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Abstract  
Percutaneous coronary intervention (PCI) is the commonest modality of 
revascularization in patients with coronary artery disease. Data suggests that 30-day 
readmissions are not uncommon. The rate of readmission after PCI is highly influenced by 
the cohort and the healthcare system studied, with 30-day readmission rates reported between 
4.7-15.6%. Understanding the reasons for readmission is important because it is a quality of 
care indicator, in addition to being a burden to patients and healthcare services.  Studies 
consistently report that majority of readmissions within 30 days are due to a cardiac related 
disorders or complication related. While there are many predictors of readmissions it is not 
known whether any of the modifiable predictors could have prevented the readmission.  This 
review aims to evaluate readmission rates, causes and predictors in the current literature.  
Furthermore, we explore the cohort inclusion criteria and patient characteristics  to better 
understand the variation in reported  readmission rates and causes across different studies. 
 
Keywords: percutaneous coronary intervention; coronary angioplasty; coronary 
revascularization; readmission; hospitalization 
Highlights 
 The rate of 30-day readmission after PCI has been reported between 4.7-15.6%. 
 The rate is highly influenced by the cohort and the healthcare system studied. 
 Majority of readmissions within 30 days are cardiac related. 
 There are many predictors of readmission following PCI. 
 It is unclear whether targeting patients with predictors could reduce readmissions. 
Introduction 
Percutaneous coronary intervention (PCI) is the most common form of 
revascularization undertaken in patients with coronary disease in both the elective and acute 
setting, accounting for 3.6% of all operating room procedures in USA in 2011.[1]  In 2007-
2008 in USA, 3,667 PCI were performed per million adults per year.[2] The growth of PCI is 
a global phenomenon that has been observed in other countries.  PCIs performed in the UK 
have more than doubled over the last decade from over 44,000 procedures in 2002 to over 
92,000 in 2013 and the numbers have levelled off since.[3] In Europe, PCI has increased 
from 184,000 procedures to 733,000 between 1992 to 2003.[4]  The rise has also been 
observed in other countries such as India,[5] China[6] and Japan.[7]  With the growth PCI, 
there has been recent concerns about the common problem of post-procedural hospital 
readmissions.[8] 
Understanding the nature and impact of readmissions is important because of its 
burden to patients and healthcare services.  Hospital readmissions are an indicator of quality 
of care[9] since they may result from actions taken or omitted during the initial hospital 
stay.[10]  Readmission may be a consequence of incomplete treatment, poor quality care or 
may reflect poor coordination of services at the time of discharge or during ongoing 
care.[11,12] Unplanned readmissions can be considered an adverse outcome for patients.  
Patients may be hospitalised because of complications related to their PCI procedure or in-
hospital management. Recognised complications related to the PCI procedure include 
contrast-induced nephropathy, thrombotic complications and major bleeding.[13,14] 
Coronary stent implantation during PCI requires dual antiplatelet therapy post procedure 
which increase the propensity to bleed and may directly contribute to gastrointestinal or 
intracranial hemorrhage.[15,16] Furthermore, readmissions are costly to healthcare services.  
In the USA, the Affordable Care Act creates financial penalties for hospitals that have risk 
adjusted readmission rates for specific conditions exceeding specific benchmarks.[17]  In the 
USA 20% of Medicare patients are readmitted within 30 days with an associated cost 
estimated at $17 billion.[18] The UK government has made a commitment to ensure hospitals 
are responsible for patients not just during their treatment but also for the 30 days after they 
are discharged and the hospital will not receive any additional payment for treatment if 
patients are readmitted within 30 days.[19] 
This literature review highlights the current evidence on readmissions after PCI.  In 
particular we will focus on the evidence surrounding early readmission among studies of PCI 
patients. 
Early admissions after PCI  
Early readmission after PCI is a more robust marker of quality of care and overall 
outcome when compared to late readmission. The association with the initial PCI weakens 
with time, as other confounding variables increasingly influence hospital admission. Table 1 
shows a summary of the studies which are described in the manuscript. 
Curtis et al conducted the first studies evaluating early admission after PCI in 2005.  
This study included 315,241 Medicare patients from 1,108 US hospitals.  The all-cause 30-
day readmission rate was 14.6%.[20] The readmission rates for individual hospitals ranged 
from 8.9% to 22.0%.  Interestingly, the study identified the 10 most frequent diagnostic codes 
for readmission and report that one-fifth of the cohort returned because of an acute 
cardiovascular condition, such as acute myocardial infarction, unstable angina, arrhythmia or 
heart failure.  Chronic ischemic heart disease, chest pain and acute cardiovascular conditions 
together account for 54.7% of all readmissions. 
These results must be interpreted in the context of the study cohort.  First, the 
Medicare database is limited to patients older than 65 years  and consequently younger, and 
possibly lower risk patients, were not included.  Secondly, hospitals which performed fewer 
than 50 PCI cases in 2005 were excluded meaning only more experienced operating sites 
were included.  However, the authors did perform an analysis of readmission rates according 
to different volume of PCI (≤200, 201 to 400 and >400) and it was consistently 14%.  
Nevertheless, there is evidence elsewhere of cut-off effects where low PCI volumes  are 
associated with inferior clinical outcomes.[21]  The authors reported many key differences 
between those patients readmitted within 30 days and patients that did not experience 
readmission. Patients who were readmitted were older, more likely to be female and have 
diabetes, heart failure, renal failure and prior ischemic heart disease. The mortality rate in 
patients readmitted was greater at 30 days compared to those who did not experience 
readmission (3.3% vs 0.6%).  A total of 30.5% of patients in the cohort had a diagnosis of 
acute myocardial infarction at baseline and these patients had significantly higher 
readmission rates (17.5%) compared to those without this diagnosis (13.6%).   
 Hannan et al  retrospectively evaluated 30-day readmissions among patients in the 
New York State PCI registry in 2007.[22]  Analysis of 40,093 patients, recorded that 15.6% 
(n=6,254) of patients were readmitted within 30 days and 20.5% (n=1,285) out of the 6,254 
total readmissions had staged procedures.  Excluding these staged procedures readmission 
rate was 12.4% (n=4,969).  This study also reported that patients who underwent PCI for 
acute myocardial infarction had greater 30-day readmission rates than those who underwent 
PCI for elective indications (17.3% vs 15.4% respectively). In terms of causes of 
readmission, out of the 4,969 patients who were readmitted without a staged PCI, 58.0% 
(n=2,883) had a cardiac diagnosis for readmission.   There are a few important considerations 
for this cohort.  This cohort had very low rates of in-hospital mortality of 0.49% (n=195).  
This may be explained by the observation that nearly half the cohort (48%) was aged less 
than 65 years old, a group excluded from the Curtis et al study.  With a large cohort of young 
patients, the rates of acute myocardial infarction at index presentation was nearly half that of 
Curtis’s study (17.3%, n=863).  The study identified many predictors of 30-day readmissions 
including: age greater than 65 years, female gender, reduced ejection fraction and triple 
vessel disease, and a number of comorbidities including: peripheral vascular disease, COPD, 
diabetes and renal failure.  Prolonged length of stay was also associated with increased odds 
of readmission. 
 Khawaja et al studied 30-day readmission rates after PCI.  Out of a total of 15,498 
cases of PCI between 1998 to 2008 in the Rochester, USA[23] 30-day readmission rates were 
9.4% which was highest for emergency procedures (13.8%), then urgent procedures (10.8%) 
and least for elective procedures (8.0%).  More than two thirds of participants readmitted 
within 30 days were readmitted because of cardiac causes. This was not defined by the study.  
This study also looked at the prognostic impact of readmission within 30 days and found that 
it was associated with significantly higher mortality at 1 year. 
Compared to the other studies, the study by Khawaja et al had more in-depth analyses 
of factors that contributed to readmissions.  This study included a unselected cohort with 289 
(1.8%) in-hospital deaths before initial discharge and there were many independent predictors 
of re-admissions including female sex (OR 1.32; 95% CI 1.17-1.48), medicare insurance (OR 
1.20; 95% CI 1.01-1.43), less than a high school education (OR 1.35; 95% CI 1.17-1.55), 
congestive heart failure at presentation (OR 1.36; 95% CI 1.15-1.60), CVA/TIA (OR 1.22; 
95% CI 1.04-1.44), moderate to severe renal disease (OR 1.46; 95% CI 1.12-1.89), COPD 
(OR 1.31; 95% CI 1.12-1.54), peptic ulcer disease (OR 1.29; 95% CI 1.05-1.59), metastatic 
cancer (OR 1.92; 95% CI 1.19-3.09) and length of stay >3 days (OR 1.59; 95% CI 1.37-
1.85).  These findings reveal the strong influence of comorbidity on readmission rates but 
there is no consideration of the effect of combinations of comorbidities and severity of the 
comorbidities.  This study was limited because it did not define the readmission diagnoses 
aside from 69% for cardiac-related reasons.  
Another important factor not considered in this 10-year study was how changes in 
practice over time might have influenced readmissions.  We would expect that over the 
course of one year in the Curtis and Hannan studies there would not be major changes in 
practice.  However, over a ten-year period one can expect significant changes in operator 
techniques / practice, clinical demographics of the patients undergoing PCI, equipment and 
stent platforms used, techniques and pharmacology that all might contribute to readmission 
rates.  
 The Guthrie Health Off-label Stent (GHOST) Registry was used as a single-centre 
study to evaluated early readmissions after PCI in a rural tertiary care setting.[24]  This study 
between 2001 and 2009 evaluated 5,706 patients and the in-hospital mortality rate was 1.7%.  
Early readmission occurred in 11.4% (n=486) of all patients and 75% (n=366) of all 
readmission returned for cardiac reasons such as unstable angina, myocardial infarction, 
repeat revascularization and heart failure.  There was no explanation of what defined non-
cardiac early readmissions.  Unlike other studies, patients with a diagnosis of myocardial 
infarction at index PCI did not have an increased risk of readmission (45% vs 42%) and this 
applied for both NSTEMI (24% vs 22%) and STEMI (21% vs 20%).  However, non-elective 
cases were predictive of readmission (72% vs 62%).  This study found that mortality rates at 
one year were significantly higher with 30-day readmission (aHR 2.2; 95% CI 1.4-3.4) but 
this was the first study to consider one-year major adverse cardiovascular outcome which was 
also significantly higher (aHR 2.2; 95% CI 1.8-2.8).     
 Again there were detailed analyses of the association between patient and procedural 
variables and readmissions.  Patients who had readmissions were more likely to be female 
and had lower body surface area.  Comorbidities also had a strong association with 
readmissions in the cohort as diabetes, cerebrovascular disease, peripheral vascular disease, 
and previous myocardial infarction were more prevalent in patients re-admitted.  Several key 
angiographic variables were further identified as predictors of readmission including AHA 
type C lesions, lesion length >28 mm, left ventricular ejection fraction <40% and intra-aortic 
balloon pump use.  This study built on existing studies by evaluating the influence of medical 
therapy at time of hospital discharge, with aspirin <325 mg (18% vs 14%) and proton pump 
inhibitor (36% vs 27%) the only drugs associated with greater readmission rates.  Similar to 
the study of Khawaja et al, readmissions were strongly associated with all one-year outcomes 
of death (7.9% vs 3.2%), myocardial infarction (5.1% vs 2.2%), stent thrombosis (2.8% vs 
0.8%) and major adverse cardiovascular events (18% vs 9.7%). 
Meadows et al conducted a study of administrative claims in a large US managed care 
plan that included 30-day readmissions after PCI in 2006.[25]  Out of the 6,687 commercially 
insured patients, 744 (11.1%) recorded an all-cause readmission within 30 days.  Nearly half 
of all admissions were for revascularization procedures (47.6%) and 27.4% had other non-
cardiovascular-related hospitalizations.  
A more recent American study was published by Wasfy et al, who evaluated 
readmissions between 2007 to 2011 in 2 hospitals.[8]  A total of 9081 patients were included, 
with 2.2% (n=207) dying during index admission and 893 (9.8%) readmitted within 30 days 
of discharge.  The most common cause for readmission was chest pain (38.1%) and 6.6% of 
patients returned for staged PCI procedure and 2.5% returned for elective CABG.  Several 
other key reasons were reported including congestive heart failure (5.9%), vascular/bleeding 
complication of PCI (4.4%), gastrointestinal hemorrhage (3.1%) and stent thrombosis (2.5%). 
The cohort had proportionally few elective procedures (18.7%) and access site was 
predominantly femoral (85.6%).  In addition, this study was able to assess whether or not 
patients were readmitted to the index hospital that undertook the PCI and the reason of 
readmission.  The most common cause for readmission to the same hospital was related to 
chronic ischemic heart disease (31%). The commonest reason for readmission to non-index 
hospital was heart failure (13.8%).  The next most common cause for admission was 
symptoms involving respiratory system and other chest symptoms (11%).  The high rates of 
respiratory and other chest symptoms may be due to the higher reported prevalence of COPD 
(20.7%) in this cohort compared to other cohorts studied (Hannan 6.1%, Khawaja 11%). 
Yost et al conducted a study of 3,255 patients who underwent PCI in the American 
College of Cardiology National Cardiovascular Data Registry.[26]  They reported that 30-day 
readmission rate was 8.0% which can be broken down into 11.9% that had complications 
related to PCI, 35.6% had non-PCI cardiac causes for readmission, 13% had noncardiac  
cause for readmission and 39.5% had an admission unrelated to the index admission.  The 
study also found that the independent predictors of 30-day readmission were female sex, 
advanced age, peripheral vascular disease, prior valvular surgery and PCI complications 
during index procedure. 
Only two studies evaluated early readmissions outside of  North America.  Moretti et 
al conducted a study of patients in an Italian cohort who underwent PCI between 2009 and 
2011.[27]  Their study of 1,192 patients recorded very low readmission rates of 4.7% (n=53) 
of which 47% of the total readmissions (n=25) were for acute coronary syndromes or heart 
failure.  This is a smaller study compared to previous studies, which may explain why only a 
few independent predictors of readmission were identified.  Age, ejection fraction, diagnosis 
of acute coronary syndrome, left main disease with implant of stent and periprocedural 
myocardial infarction were independent predictors of 30-day cardiac readmission.  There 
were also higher rates of adverse events at 30 days in the readmission group including 
myocardial infarction (6% vs 0%), PCI (60% vs 0.6%).  Out of all readmissions, 10 were 
staged PCI or staged cardiac surgery that means after excluding these cases the readmission 
rate is even lower (3.6%).  The other study, by Przybysz et al, studied outcomes at a Polish 
centre between 2008 and 2009.[28]  The in-hospital mortality rate was 2% (n=40) and a total 
of 1897 patients were included in the analysis of which 277 (14.6%) were readmitted at 30 
days.  The readmitted group was older (67.5 vs 65.3 years) and with a greater prevalence of 
congestive heart failure (27.8% vs 18.6%) and chronic renal insufficiency (9.4% vs 4.6%).  
Readmitted patients were also more likely to die at 30 days (3.6% vs 0.3%). 
Predictors of readmission 
 Seven of the include studies described independent predictors of readmission (Table 
3a).  A few of the predictors were reported in more than one studies and these were pooled in 
meta-analysis.  The results suggest that female sex, peripheral vascular disease, peripheral 
vascular disease, diabetes mellitus, renal failure and non-elective PCI were predictive of 
readmission (Table 3b). 
Mortality among patients who have early readmission compared to no readmission 
 Five of the include studies describe mortality associated with patients who had early 
readmission compared to those who were not readmitted (Table 4).  All the studies suggest 
greater risk of mortality among patients with readmission. 
Discussion 
 The published evidence suggests that 30-day readmission following PCI is important 
because it is common and is associated with poor outcome. The rate depends on the 
population studied.  The risk profile of the cohort studies is important, as the prevalence of 
high-risk cases, such as acute coronary syndrome, will affect readmission rates.  In addition, 
there are other more complex factors, such as proportion of older patients and the prevalence 
of comorbidities influencing the propensity of a patient to be readmitted within 30 days.  
Furthermore, the processes of care and availability of alternatives to PCI may affect rates of 
readmission, as different centres may have different thresholds for managing patients 
conservatively or undertaking PCI or different protocols for referral for coronary bypass.  The 
variation in processes of care is not captured or considered in many studies.   
 The causes of readmissions are shown in Table 2.  They can be divided into cardiac 
and non-cardiac causes for readmission.  We observed variation in the frequency of these 
causes across each study.  We believe this reflects differences in the population studied in 
terms of factors which influence readmission.  However, most studies reported that cardiac 
causes represent the most common reason for readmission. 
 The potential reasons for post PCI hospitalisation can be divided into hospital factors, 
patient factors, pre-existing disease factors, procedural factors and medication related factors 
and these have been explored in PCI and non-selected elderly cohorts.  In terms of hospital 
factors, lack of documented patient or family education and previous admission within 30 
days was associated with increased readmission in a non-selected elderly cohort.[29]  For 
patient factors, Aggarwal et al conducted a study of PCI patients and found a higher 
readmission rate for patients who were age 65 years or greater, female gender, Medicaid 
insurance, low median income for zip code and metropolitan areas.[30]  The finding that low 
income was associated with greater readmission has been also reported in non-selected 
cohorts.[31]  The influence of comorbidities on readmissions has been demonstrated by 
several PCI studies with diabetes,[32] renal failure,[32,33] chronic obstructive pulmonary 
disease[33] and hypertension[32,34] associated with greater risk of readmissions.  In non-
selected elderly studies, readmission is associated with number of comorbidities and having 
depression.[29,35]  The PCI procedure itself can lead to complications such as coronary 
dissection,[36] coronary perforation,[37] major bleeding,[13] stent thrombosis,[38] 
stroke,[15] radial artery occlusion[39] and contrast nephropathy[40] and some of these 
complications may lead to readmission.  Medication related factors can also affect 
readmission as there is increased risk of readmission with any medication dosage change in 
the 48 hours prior to discharge.[41]   Secondary prevention medications after PCI might 
reduce chest pain and re-infarction but carry side effects.  For example, dual antiplatelet 
drugs can increase the propensity to bleed and cause admissions related to bleeding 
complications.[42]  Use of beta-blockers and ACE inhibitors can low blood pressure and 
cause postural hypotension that may result in admissions for falls in the elderly.[43] 
 Stent thrombosis is one of the feared complications following PCI as mortality after 
this complication may be as high as 45%.[44] The pathophysiology of stent thrombosis 
involves stent mal-apposition to the vessel wall with subsequent platelet adhesion, activation 
and thrombus formation.[38] As time progresses after stent implantation, endothelial cells 
cover the stent and the need for dual antiplatelet inhibition decreases, particularly for 
contemporary thin walled platforms, with rapid drug elution where dual antiplatelet therapy 
can be discontinued earlier than previously.[45]  Cytostatic drugs in drug eluting stents 
reduce smooth muscle growth thereby reducing intimal hyperplasia and restenosis, but may 
also inhibit endothelialisation aswell as causing inflammatory and hypersensitivity reactions 
that all contribute to a pro-thrombotic environment.[46]  Clinical factors associated with stent 
thrombosis includes procedure and lesion related parameters (e.g. coronary dissection, slow 
flow, stent mal-apposition, under-expansion of stent), patient characteristics (e.g. diabetes, 
advanced age, high platelet reactivity) and antiplatelet therapy (inadequate intensity of 
therapy, non-compliance, clopidogrel resistance and premature cessation of antiplatelet 
therapy).[38]  As a result optimisation of stent results and optimal antiplatelet therapy is of 
crucial importance in preventing stent thrombosis, although some patients have impaired 
response to antiplatelet therapy[47] and cessation of dual antiplatelet therapy is linked to stent 
thrombosis.[48] 
 Our review includes nationwide or multicentre cohorts, which can account for the 
variation and provide a balanced overall risk profile.  However, these studies have not 
considered the readmission rates at the hospital-level and there may be patterns in hospitals 
that increase the likelihood of readmissions, such as those with low volume of procedures and 
the proportion of procedures undertaken by trainees.  There were a few single hospital studies 
that are more likely to provide uniformity of delivered care with a cohort that has a more 
consistent risk profile.  The cause of readmission is just as important as being aware that 
patients are being readmitted, as some readmissions may be predictable and avoidable, while 
others may not; our review of the literature suggests that the majority of readmissions are for 
cardiac problems.  In centres where most cases are elective day case procedures the cardiac 
problem may be addressed but any other existing illnesses are less likely to be managed 
unlike inpatient settings where a more holistic approach is taken.  The majority of studies are 
from the United States which has a different healthcare system than that in Europe.  Some of 
the studies are from insurance database registries that may only represent certain more 
affluent patients and not reflect the overall population.  At the same time, patients from a 
system where there is both private and insurance-based healthcare is very different from one 
providing universal health care, such as in as the United Kingdom or France.  Data derived 
from centres from outside North America is limited, with only two studies reporting 
outcomes and the applicability of these two centre studies to practice outside of the United 
States is limited.  
 There are limited studies that evaluate measures to reduce post-PCI readmissions.  
First, it is clear that compliance to drug eluting stent therapy is paramount and patients should 
be well educated about the risks associated with discontinuation of antiplatelet therapy.  
Adherence to recommended guidelines regarding other secondary prevention drugs such as 
beta-blockers, angiotensin converting enzymes inhibitors/angiotensin II receptor blockers and 
statin therapy unless there is contraindication should be promoted.  There is no evidence that 
early outpatient follow up can reduce readmissions however it makes clinical sense that high 
risk patients, especially those who have coronary disease which is left untreated after PCI 
procedure, should be followed up early.  Use of cardiac monitoring post procedure may be of 
benefit to identify life threatening arrhythmias and echocardiographic evaluation cardiac 
function after PCI may be useful to identify high risk patients prior to discharge who may 
warrant device implantation or early follow up. 
Conclusions 
 Readmission after PCI is common and its rate is highly influenced by the type of 
cohort studied.  Most of the literature is based on studies derived from the United States that 
has a unique healthcare delivery model. It is unclear if these results are generalisable to other 
countries.  There is clear evidence that majority of readmissions within 30 days are cardiac 
related.  While there are many predictors of readmission following PCI, it is not known 
whether targeting patients with modifiable predictors could prevent or reduce the rates of 
readmission.   
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Table 1: Description of studies 
Study ID Study 
design;Year;Country 
No. of 
participants 
 
Participant 
selection 
criteria 
Rate of 
readmission 
Top 10 causes of readmission 
 
Curtis 
2009 
Retrospective cohort 
study; 2005; USA. 
315,241 Medicare 
patients who 
underwent 
PCI. 
30-day readmission 
rate: 
45,964/315,241 
(14.6%).  
Chronic ischemic  heart disease 29.2% 
Heart failure 9.6% 
Chest pain 6.7% 
Myocardial infarction 4.7% 
Arrhythmia 4.5% 
Pneumonia 4.5% 
Atherosclerosis 1.8% 
Procedural complication 1.7% 
General symptoms 1.5% 
Renal failure 1.4% 
Hannan 
2011 
Retrospective cohort 
study; 2007; USA. 
40,093 Patients in 
New York 
State PCI 
registry. 
30-day readmission 
rate: 6,524/40,093 
(15.6%). 
Chronic ischemic heart disease 22.46% 
Chest pain 10.79% 
Heart failure 8.17% 
Complication as a result of precious procedure/medical 
care 6.98% 
Other noncardiac disease 6.08% 
Digestive system 6.08% 
Target vessel PCI 5.03% 
Respiratory system 4.69% 
Arrhythmias 4.33% 
Myocardial infarction 3.44% 
Harjai 
2012 
Prospective cohort 
study; 2001-2009; 
USA. 
4,262 Patients in the 
Guthrie Off-
label Stent 
Registry. 
30-day readmission 
rate: 486/4262 
(11.4%). 
Cardiac readmission 366/486 (75.3%). 
Noncardiac readmission 120/486 (24.7%). 
Khawaja 
2012 
Prospective cohort 
study; 1998-2008; 
USA. 
15,498 Patients who 
underwent PCI 
at St. Marys 
30-day readmission 
rate: 1,459/15,498 
(9.4%). 
Cardiac readmission 1,003/1,498 (67.0%). 
Noncardiac readmission 495/1,498 (33.0%). 
Hospital in 
Rochester. 
Meadows 
2012 
Retrospective cohort 
study; 2006; USA. 
6,687 Patients with 
ACS and PCI 
in a 
administrative 
claims 
database. 
30-day readmission 
rate: 744/6687 
(11.1%). 
Non-cardiovascular readmission 41.4%. 
Revascularization procedure 35.5%. 
Other cardiovascular 14.2%. 
Chest pain 6.1%. 
Heart failure 1.7%. 
Stroke 1.0%. 
Moretti 
2015 
Prospective cohort 
study; 2009-2011; 
Italy. 
1,192 Patients who 
underwent PCI 
in a single 
center Italy. 
30-day readmission 
rate: 53/1,192 
(4.7%). 
Unstable angina 11/53 (20.8%) 
Chest pain 7/53 (13.2%) 
Staged PCI 7/53 (13.2%) 
Heart failure 7/53 (13.2%) 
Myocardial infarction 4/53 (7.5%) 
Postinfarction angina 3/53 (5.7%) 
Staged cardiac surgery 3/53 (5.7%) 
Implantable cardioverter defibrillator implant 2/53 
(3.8%) 
Atrioventricular block 2/53 (3.8%) 
Abdominal pain 2/53 (3.8%) 
Przybysz-
Zdunek 
2012 
Cohort study; 2008-
2009; Poland. 
2,039 Patients who 
underwent PCI 
in Poland. 
30-day readmission 
rate: 277/2,039 
(14.6%). 
 
Cardiac problems 79.4% (44.4% stable coronary 
disease, 18.8% myocardial infarction and unstable 
angina, 9.0% congestive heart failure, 2.9% cardiac 
arrhythmia, 0.4% cardiac arrest, 4% other like 
structural heart disease and hypertension).  
Gastrointestinal 5.1% 
Cerebrovascular disease 2.2% 
Cancer 2.2% 
Diabetes and its complications 1.8% 
Respiratory disease 1.4% 
Renal insufficiency 1.1% 
Other 6.9% 
Wasfy Retrospective cohort 9,288 Patients who 30-day readmission Chest pain or other symptoms concerning for angina 
2014 study; 2007-2011; 
USA. 
underwent PCI 
in the Partners 
Healthcare 
Hospitals in 
USA. 
rate: 893/9,288. 341 (38.1%) 
Staged PCI without new symptoms 59 (6.6%) 
Congestive heart failure 53 (5.9%) 
Vascular/bleeding complications of PCI 39 (4.4%) 
Gastrointestinal hemorrhage 28 (3.1%) 
Stent thrombosis 22 (2.5%) 
Syncope or presyncope: 22 (2.5%) 
Elective peripheral procedure or surgery not related to 
PCI 20 (2.2%) 
Elective CABG 19 (2.1%) 
Cholecystitis, colitis/enteritis, pancreatitis, cholangitis 
or abdominal pain 18 (2.0%) 
Yost 2013 Prospective cohort 
study; 2007-2010; 
USA. 
3,255 Patients who 
underwent PCI 
in the 
American 
College of 
Cardiology 
National 
Cardiovascular 
Data Registry. 
30-day readmission 
rate: 262/3,255. 
Cardiac reason for readmission related to index 
admission 93 (35.6%)  Unstable angina 28 (10.7%)  Congestive heart failure 22 (8.4%)  Staged PCI 13 (5.0%) 
PCI complication 31 (11.9%)  In-stent thrombosis 12 (4.6%) 
Noncardiac reason related to index admission 32 
(12.2%)  Infection/sepsis (2.3%) 
Unrelated to index admission 105 (40.2%)  Non-cardiac chest pain 27 (10.3%)  Gastrointestinal cause 20 (7.7%)  Infection/sepsis (3.4%)  Neurological cause 8 (3.1%) 
 
Table 2: Causes of unplanned readmission* 
Cardiac causes Noncardiac causes 
Chronic ischemic heart disease 
Chest pain 
Heart failure 
Arrhythmias 
Myocardial infarction 
Atherosclerosis 
Target vessel percutaneous coronary 
intervention 
Complication as a result of previous 
procedure/medical care 
Digestive system 
Noncardiac circulatory system 
Respiratory system 
Endocrine, nutritional, and metabolic system 
Kidney and urinary tract 
Infectious and parasitic diseases 
Musculoskeletal system and connective 
tissue 
Cancer 
Injuries, poison and toxic effect of drugs 
Skin, subcutaneous tissue and breast 
Blood and blood-forming organs and 
immunologic disorders 
Other noncardiac disease 
*Adapted from Hannan EL, Zhong Y, Krumholz H, Walford G, Holmes DR, Stamato NJ, 
Jacobs AK, Venditti FJ, Sharma S, King III, SB. 30-day readmission for patients undergoing 
percutaneous coronary interventions in New York State. JACC Cardiovasc Interv 
2011;4:1335-1342. 
Table 3: Predictors of readmission 
Study ID Predictors of readmission 
Curtis 2009 Volume of PCI: ≤200: 14.7%, 201-400: 14.3%, >400: 14.8%. Profit 
status: not-for-profit: 14.7%, for profit 14.3%, governmental 14.2%. 
Teaching status: Council of Teaching Hospitals 15.0%, non-Council of 
Teaching Hospital 14.1%, nonteaching 14.6%.  Speciality hospital: heart 
hospital 13.1%, nonspeciality hospital 14.6%.  
Hannan 2011 Age >65 OR 1.02 (1.01-1.02), female OR 1.32 (1.25-1.40), ejection 
fraction <20% OR 2.08 (1.62-2.66), 20%-29% OR 1.31 (1.13-1.53), 30-
39% OR 1.20 (1.07-1.35), ≥3 number of diseased vessels OR 1.12 (1.01-
1.23), pre-procedural MI 1-14 days OR 1.16 (1.05-1.27), peripheral 
vascular disease OR 1.43 (1.29-1.59), malignant ventricular arrhythmia 
OR 1.50 (1.03-2.18), COPD OR 1.60 (1.44-1.77), diabetes OR 1.21 (1.13-
1.30), renal failure creatinine 1.6-3.0 mg/dl OR 1.24 (1.12-1.37), 
creatinine >3.0 mg/dl OR 1.95 (1.33-2.86), dialysis OR 1.83 (1.54-2.18). 
Harjai 2012 Female OR 1.44 (1.15-1.80), non-elective PCI OR 1.60 (1.26-2.04), 
peripheral artery disease OR 1.64 (1.22-2.20), prior myocardial infarction 
OR 1.31 (1.01-1.70), PCI of LAD OR 0.78 (0.62-0.98), lesion length 
>28mm OR 1.55 (1.16-2.07), Aspirin dose <325 mg/day OR 1.35 (1.01-
1.80), PPI use OR 1.41 (1.12-1.77). 
Khawaja 
2012 
Female OR 1.32 (1.17-1.48), medicare insurance OR 1.20 (1.01-1.43), 
less than high school education OR 1.35 (1.17-1.55), distance travelled 
(per 100 miles) OR 0.96 (0.92-0.99), MI 1-7 days OR 0.81 (0.69-0.94), 
CHF at presentation OR 1.36 (1.15-1.60), CVA/TIA OR 1.22 (1.04-1.44), 
moderate to severe renal disease OR 1.46 (1.12-1.89), COPD OR 1.31 
(1.12-1.54), peptic ulcer disease OR 1.29 (1.05-1.59), metastatic cancer 
OR 1.92 (1.19-3.09), elective PCI OR 0.80 (0.70-0.91), procedural 
success OR 0.68 (0.55-0.84), length of stay OR 1.59 (1.37-1.85), PCI date 
(per year) OR 0.96 (0.94-0.99). 
Moretti 2015 Periprocedural myocardial infarction OR 4.5 (1.1-16.8). 
Przybysz-
Zdunek 2012 
Age OR 1.01 (1.00-1.03), congestive heart failure OR 1.52 (1.10-2.09) 
and chronic renal insufficiency OR 1.70 (1.04-2.79). 
Yost 2013 Prior valve surgery OR 3.72 (2.16-6.40), peripheral artery disease OR 
1.60 (1.16-2.21), diabetes mellitus OR 1.51 (1.16-1.97), pre-PCI left 
ventricular ejection fraction OR 0.94 (0.90-0.99), STEMI diagnosis OR 
1.67 (1.06-2.65), NSTEMI diagnosis OR 1.80 (1.15-2.81), unstable 
angina diagnosis OR 1.99 (1.33-3.00) and worse lesion pre-stenosis OR 
0.85 (0.76-0.98). 
 
Table 3b: Pooled results for independent predictors of readmission 
Independent predictor No. of studies Pooled odds ratios (95% CI) 
Female sex 3 1.33 (1.26-1.39) 
Pre- or peri-procedural MI 3 1.08 (0.74-1.56) 
Peripheral vascular disease 3 1.46 (1.33-1.61) 
Diabetes mellitus 2 1.30 (1.06-1.59) 
Renal failure 3 1.54 (1.28-1.86) 
Non-elective PCI 2 1.38 (1.09-1.76) 
 
Table 4: Mortality rate for patients with early readmission vs no readmission 
 
Study ID Mortality rate for those readmission vs no readmission 
Curtis 2009 30-day mortality for readmitted vs non-readmitted: 1,438/43,566 (3.3%) 
vs 1,529/254,829 (0.6%).  
Harjai 2012 1 year mortality for early readmission vs no readmission: 34/428 (7.9%) 
vs 117/3694 (3.2%), aHR 2.12 (1.44-3.34).  
Khawaja 
2012 
30-day readmission and 1 year mortality aHR 1.38 (1.08-1.75). 
Moretti 2015 All-cause mortality for ACS/heart failure readmission vs no readmission: 
OR 3.3 (1.1-8.8).  
Przybysz-
Zdunek 2012 
30-day mortality for readmitted vs non-readmitted: 10/277 (3.6%) vs 
5/1,620 (0.3%). 
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